✦ LIBER ✦

VEGF and therapeutic opportunities in cardiovascular diseases

✍ Scribed by Wolfgang Schaper; Ivo Buschmann

Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 56 KB
Volume: 10
Category: Article
ISSN: 0958-1669
DOI: 10.1016/s0958-1669(99)00032-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiovascular disease risk in rheumatoi

Cardiovascular disease risk in rheumatoid arthritis: Progress, debate, and opportunity

✍ Henry R. Kramer; Jon T. Giles 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 137 KB 👁 2 views

Opportunities, challenges, and caveats o

Opportunities, challenges, and caveats of successful molecular imaging of cardiovascular diseases

✍ Bodo Levkau 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 103 KB

Salt restriction in kidney disease—a mis

Salt restriction in kidney disease—a missed therapeutic opportunity?

✍ Eberhard Ritz; Otto Mehls 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 206 KB

Therapeutic opportunities in dengue infe

Therapeutic opportunities in dengue infection

✍ Caio T. Fagundes; Vivian V. Costa; Daniel Cisalpino; Danielle G. Souza; Mauro M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Status of therapeutic gene transfer to t

Status of therapeutic gene transfer to treat cardiovascular disease in dogs and cats

✍ Meg Sleeper; Lawrence T. Bish; Mark Haskins; Katherine P. Ponder; H. Lee Sweeney 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 740 KB

Therapeutic apheresis in rheumatological

Therapeutic apheresis in rheumatological diseases

✍ Max Hamburger; Gayl Rogers 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 2 views

Dr. Hamburger was asked whether he would recommend the use of cytoxin or lymphacytapheresis first in the treatment of rheumatoid arthritis. He stated that he would recommend lymphacytapheresis first, especially in relatively young patients because of the multiple side effects and the risk of long-te